Conjugate (MTC-220) of muramyl dipeptide analogue and paclitaxel prevents both tumor growth and metastasis in mice.

Abstract

1 (MTC-220), a conjugate of paclitaxel and a muramyl dipeptide analogue, has been synthesized as a novel agent of dual antitumor growth and metastasis activities. In vitro and in vivo tests show that 1 retains its ability to inhibit tumor growth. It is superior to paclitaxel in its ability to prevent tumor metastasis in Lewis lung carcinoma and 4T1-tumor-bearing mice. The present studies indicate that 1 suppresses myeloid derived suppressor cell accumulation in the spleen and bone marrow of tumor-bearing mice and also represses inflammatory cytokines in tumor tissue. These results demonstrated that 1 could be a potential therapeutic and preventive agent for cancer growth and metastasis.

• Authors: Yao Ma, Nan Zhao, Gang Liu
• Journal: Journal of medicinal chemistry (J Med Chem) Vol. 54 Issue 8 Pg. 2767-77 (Apr 28 2011) ISSN: 1520-4804 [Electronic] United States
• PMID: 21405130 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cytokines
• Dipeptides
• Inflammation Mediators
• MTC-220
• Acetylmuramyl-Alanyl-Isoglutamine
• Paclitaxel

Topics

• Acetylmuramyl-Alanyl-Isoglutamine (pharmacology)
• Animals
• Bone Marrow Cells (drug effects)
• Breast Neoplasms (metabolism, pathology)
• Carcinoma, Lewis Lung (pathology)
• Cell Division (drug effects)
• Cell Line, Tumor
• Chromatography, High Pressure Liquid
• Cytokines (metabolism)
• Dipeptides (pharmacology)
• Female
• Humans
• Inflammation Mediators (metabolism)
• Mice
• Mice, Nude
• Neoplasm Metastasis (prevention & control)
• Paclitaxel (analogs & derivatives, pharmacology)